T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2326
Regenxbio
RGNX
$704M
| $562K | ﹤0.01% |
38,995
+3
| +0% | +$37 |
|
|
NFBK
2327
DELISTED
Northfield Bancorp
NFBK
| $559K | ﹤0.01% |
48,890
+2,063
| +4% | +$22.9K |
|
2328
Sable Offshore Corp
SOC
$773M
| $559K | ﹤0.01% |
61,886
+1,856
| +3% | +$17.5K |
|
2329
Bowman Consulting
BWMN
$731M
| $558K | ﹤0.01% |
16,880
+865
| +5% | +$32.8K |
|
|
AD
2330
Array Digital Infrastructure
AD
$3.09B
| $558K | ﹤0.01% |
10,399
| – | – |
|
2331
Revolution Medicines Inc Warrant
RVMDW
$123M
| $555K | ﹤0.01% |
595,934
-1
| -0% | -$1 |
|
2332
Ethan Allen Interiors
ETD
$583M
| $554K | ﹤0.01% |
24,255
+1,145
| +5% | +$28.6K |
|
|
OSG
2333
Octave Specialty Group
OSG
$212M
| $552K | ﹤0.01% |
70,941
| – | – |
|
2334
Alpha and Omega Semiconductor
AOSL
$916M
| $552K | ﹤0.01% |
27,858
+1,222
| +5% | +$28.9K |
|
2335
American Express Global Business Travel
GBTG
$4.94B
| $552K | ﹤0.01% |
72,097
+22,382
| +45% | +$174K |
|
2336
NVE Corp
NVEC
$563M
| $552K | ﹤0.01% |
9,290
-1,125
| -11% | -$75.2K |
|
2337
FS KKR Capital
FSK
$3.49B
| $551K | ﹤0.01% |
37,202
+10,296
| +38% | +$156K |
|
2338
SFL Corp
SFL
$1.61B
| $551K | ﹤0.01% |
70,453
+4,340
| +7% | +$33.3K |
|
2339
State Street Technology Select Sector SPDR ETF
XLK
$125B
| $551K | ﹤0.01% |
3,824
+424
| +12% | +$61.2K |
|
2340
MasterCraft Boat Holdings
MCFT
$598M
| $549K | ﹤0.01% |
29,032
| – | – |
|
|
ONIT
2341
Onity Group
ONIT
$330M
| $549K | ﹤0.01% |
11,984
+2,539
| +27% | +$104K |
|
|
ONTF
2342
DELISTED
ON24
ONTF
| $547K | ﹤0.01% |
68,670
+13,600
| +25% | +$77K |
|
2343
PDF Solutions
PDFS
$2.13B
| $547K | ﹤0.01% |
19,156
+2,330
| +14% | +$64.5K |
|
|
NESR
2344
National Energy Services Reunited Corp
NESR
$3.62B
| $546K | ﹤0.01% |
34,807
+2,739
| +9% | +$35.9K |
|
2345
Employers Holdings
EIG
$871M
| $545K | ﹤0.01% |
12,607
-624
| -5% | -$25.4K |
|
2346
Microvast
MVST
$341M
| $543K | ﹤0.01% |
193,597
+15,360
| +9% | +$64.2K |
|
|
EHAB
2347
DELISTED
Enhabit
EHAB
| $540K | ﹤0.01% |
58,556
+3,390
| +6% | +$29.4K |
|
2348
Alto Neuroscience
ANRO
$1.26B
| $539K | ﹤0.01% |
30,228
-29,200
| -49% | -$368K |
|
|
GOLD
2349
Gold.com Inc
GOLD
$1.27B
| $538K | ﹤0.01% |
15,772
+1,175
| +8% | +$33.6K |
|
2350
Vaalco Energy
EGY
$592M
| $538K | ﹤0.01% |
147,666
+42,177
| +40% | +$156K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.